**Developing and evaluating multimedia information resources to improve engagement of children, adolescents and their parents with trials (TRECA study): Study Protocol for a series of linked randomised controlled trials**

**Authors:**

Jacqueline Martin-Kerry, Department of Health Sciences, University of York, Heslington, York, YO10, 5DD, UK; jackie.martin-kerry@york.ac.uk

Peter Bower, MRC North West Hub for Trials Methodology Research, NIHR School for Primary Care Research, University of Manchester M13 9PL, UK; peter.bower@manchester.ac.uk

Bridget Young, MRC North West Hub for Trials Methodology Research, Department of Psychological Sciences, Institute of Psychology, Health and Society, University of Liverpool, L69 3GB, UK; Bridget.Young@liverpool.ac.uk

Jonathan Graffy, Department of Public Health and Primary Care, University of Cambridge, Institute of Public Health, Forvie Site, Robinson Way, Cambridge, CB2 0SR, UK; jpg43@medschl.cam.ac.uk

Rebecca Sheridan, Department of Health Sciences, University of York, Heslington, York, YO10, 5DD, UK; rebecca.sheridan@york.ac.uk

Ian Watt, Department of Health Sciences, University of York, Heslington, York, YO10, 5DD, UK; ian.watt@york.ac.uk

Paul Baines, Paediatric Intensive Care Unit, Alder Hey Hospital, Liverpool, L12 2AP, UK; P.Baines@liverpool.ac.uk

Catherine Stones, School of Design, Clothworkers’ Central, University of Leeds, LS2 9JT, UK; C.M.Stones@leeds.ac.uk

Jennifer Preston, NIHR Alder Hey Clinical Research Facility, University of Liverpool, Institute in the Park, Alder Hey Children's NHS Foundation Trust, Eaton Rd, Liverpool, L12 2AP, UK; jennifer.preston@liverpool.ac.uk

Steven Higgins, School of Education, University of Durham, DH1 3LE, UK; s.e.higgins@durham.ac.uk

Carrol Gamble, Institute of Translational Medicine, University of Liverpool, L69 3GB, UK; C.Gamble@liverpool.ac.uk

Peter Knapp\*, Department of Health Sciences and the Hull York Medical School, University of York, Heslington, York, YO10, 5DD, UK; peter.knapp@york.ac.uk

\* Corresponding author

**Abstract**

**Background:** Randomised controlled trials are widely established as the best method for testing health interventions whilst minimising bias. However, recruitment and subsequent retention of children and adolescents in healthcare trials is challenging. Participant information sheets are often lengthy and difficult to read and understand. Presenting key information using multimedia may help to overcome these limitations and better support young people and their parents in deciding whether to participate in a clinical trial.

**Methods:** The TRECA (TRials Engagement in Children and Adolescents) studyhas two phases. The first phase involves a qualitative study with children and adolescents and their parents to inform the development of multimedia information resources and iterative user testing to refine the resources. The second phase will embed the use of the multimedia information resources into six host trials in the United Kingdom. Patients and their parents approached to participate in the host trials will be randomly allocated to either use the multimedia information resource in conjunction with standard participant information sheets, the multimedia information resource alone, or the standard participant information sheets alone. The primary outcome will be the effect of the multimedia information resources on recruitment into trials. Other outcomes measured include the effect of multimedia information resources on retention of participants into the host trials and the impact on family members’ decision-making processes, when compared to standard participant information sheets alone.

**Discussion:** This study will inform whether multimedia information resources, when developed using participatory design principles, are able to increase recruitment and retention of children and adolescents into trials. There is also the potential for patients to make better informed decisions through the use of multimedia information resources. The multimedia information resources also have the potential to assist with providing information on other healthcare decisions outside of clinical trials.

**Trial registration:** ISRCTN registry: ISRCTN73136092 (DOI 10.1186/ISRCTN73136092); registered 24 August 2016

**Keywords**

Multimedia, Intervention, Trial participation, Child, Adolescent, Information, Recruitment, Retention, Decision making, Consent, Parent

**Background**

The effectiveness and safety of healthcare interventions is best determined through randomised controlled trials (RCTs) [[1](#_ENREF_1), [2](#_ENREF_2)]. However, major barriers to the successful conduct and outcome of clinical trials are levels of recruitment and retention. In the UK, only a small proportion of trials actually recruit successfully to time and target [[3-6](#_ENREF_3)]. Furthermore, in practice, it remains relatively uncommon for a patient to participate in a clinical trial despite the development of National Health Service (NHS) organisational structures which facilitate the integration of clinical research and patient care [[7](#_ENREF_7)], for example the Clinical Research Networks (CRNs). Inadequate recruitment or retention have implications not only for conclusive results but also external validity and generalisability of the trial findings [[8](#_ENREF_8)].

There is now international recognition of the importance of paediatric clinical trials to inform healthcare decisions for children and adolescents [[9-12](#_ENREF_9)]. High quality trials involving children are essential to ensure that medication and treatments used in children are effective and safe [[9](#_ENREF_9), [11](#_ENREF_11), [12](#_ENREF_12)]. The lack of successful clinical trials leads to many healthcare decisions for children and adolescents being made with inadequate evidence, including evidence extrapolated from trials involving adults [[12](#_ENREF_12)]. Only six per cent of recently registered clinical trials in the UK involved children [[7](#_ENREF_7)]. The publication rate of trials in adults has almost doubled over a twenty year period, a rate increase that is around six times higher than for paediatric trials over the same period [[13](#_ENREF_13)]. In the past this low rate of paediatric trials was thought to be mainly due to a concern for the vulnerability of children leading to a reluctance by clinicians to undertake clinical trials with young children [[7](#_ENREF_7), [14](#_ENREF_14)]. High rates of patient or parent refusal have also been identified as a key barrier for successful completion of these trials [[15](#_ENREF_15)], although a recent study has shown lower refusal rates for paediatric trials involving therapeutic drugs [[16](#_ENREF_16)].

A potential barrier to recruitment and retention is the information provided to potential trial participants [[2](#_ENREF_2), [17](#_ENREF_17), [18](#_ENREF_18)]. How children and parents make decisions regarding participation in research and what information is important to them, both remain areas of uncertainty [[17](#_ENREF_17), [19](#_ENREF_19), [20](#_ENREF_20)]. Conventionally, participant information about a trial is provided in printed form. These documents should be understandable to potential trial participants and assist their decision-making [[21](#_ENREF_21)]. However, the format of this information has received recurrent criticism, notably for being too long, difficult and technical [[22-25](#_ENREF_22)]. Furthermore, the content of trial sheets is mostly guided by regulatory agencies and can be inconsistent with what patients want to know [[17](#_ENREF_17), [22](#_ENREF_22), [26](#_ENREF_26)]. A number of studies report that trial participants do not understand information contained within participant information sheets [[27](#_ENREF_27), [28](#_ENREF_28)] and that the information can be very wordy and overwhelming [[22](#_ENREF_22), [29](#_ENREF_29)]. Potential participants who have lower levels of literacy are most likely to be affected by this [[30](#_ENREF_30)]. Furthermore, good graphic design is often lacking in participant information sheets, such as a structure that aids navigation of the information, and visual appeal to invite and engage the reader. For example, written information should inform a decision about participation, but may act more as a prospectus for the trial and as a contract between researchers and the participant [[31](#_ENREF_31)]. Re-writing, re-designing and user testing of trial information can produce an understandable and preferred resource [[32-34](#_ENREF_32)].

An alternative for providing information to potential trial participants is through the use of a multimedia information (MMI) resource [[30](#_ENREF_30), [35](#_ENREF_35), [36](#_ENREF_36)], which presents key information using a combination of video, animation, text and audio through a website. However, research is needed to identify and evaluate different ways of presenting multimedia information about research to children and parents [[22](#_ENREF_22)]. Multimedia presentation can be understood through reading, listening and watching and allows people with different preferences to use the resource effectively [[30](#_ENREF_30)]. The MMI will contain all key information that would be found in a written participant information about the trial but will focus on information deemed important for children, adolescents and their parents [[17](#_ENREF_17), [35](#_ENREF_35)] when deciding whether to participate in a trial. Furthermore, multimedia information can enable the patient to select the order in which they access the information and allows people with different preferences to use the resource more effectively. Finally people’s familiarity with websites and the frequency of their use, means that MMIs presented on a computer (or smartphone) may now be used intuitively and easily by most people.

In educational settings it has been estimated that individuals will remember approximately 10 per cent of what they read, 20 per cent of what is heard, 30 per cent if they can visualise and hear the information, and 50 per cent if they observe someone doing something with an explanation [[37](#_ENREF_37)]. Multimedia, which involves using more than one medium of expression or communication, has been shown to be at least as effective as printed information [[38](#_ENREF_38)] and often more effective in informing people [[39-41](#_ENREF_39)]. Informational MMIs about medical procedures can improve patient knowledge [[42](#_ENREF_42), [43](#_ENREF_43)] but some have had variable impact on participant understanding [[44](#_ENREF_44)]. However a recent trial of children and adolescents undergoing endoscopy showed that presentation of information in electronic format produced more certain consent decisions, compared to printed information [[45](#_ENREF_45)]. There is limited information about the effect of multimedia patient information on trial recruitment rates [[35](#_ENREF_35), [36](#_ENREF_36)], although a relevant study is underway examining the use of MMI in trials recruiting adults in the UK [[46](#_ENREF_46), [47](#_ENREF_47)]. Furthermore, studies using multimedia to improve children’s understanding of clinical trials have demonstrated improved understanding when compared with those using traditional paper-based information [[28](#_ENREF_28)]. There are a number of paediatric studies, particularly in the United States, using video for informed consent within a website format; however, the structure of this information presentation is restrictive, requiring users to view the video from start to finish [[48](#_ENREF_48)]. MMIs have the potential to inform and engage potential trial participants in ways that printed information can struggle to do (see Figure 1 for possible effectiveness pathway).

The TRECA (TRials Engagement in Children and Adolescents) study will develop two MMIs through the use of participatory design involving individual and focus group interviews with children and adolescents with long-term health conditions and their parents (see Figure 2 [[49](#_ENREF_49)]). This will ensure that the MMIs are developed to meet the needs and preferences of potential end users. The study will examine whether providing key information about clinical trials through the use of multimedia information resources increases recruitment and retention and enables better decision making of children and adolescents participating in trials in the UK.

**Methods/Design**

**Aims**

The aims of TRECA are to evaluate the potential for MMIs to improve the quality of decision-making about participation in healthcare trials involving children and adolescents with long-term health conditions, and to assess the impact of MMIs on trial recruitment and retention and the quality of decision-making.

The objectives of the TRECA study are:

* To involve children and adolescents with long-term health conditions; their parents; and trial researchers and clinicians, in the development of two MMIs, for use when children and adolescents are being asked to consider participation in a healthcare trial.
* To obtain and analyse qualitative data from focus groups with members of key stakeholder groups (i.e. children and adolescents with long-term health conditions; parents; clinicians; trial managers) to ensure that the content and format of the MMIs reflect their needs and preferences.
* To user test the MMIs with children and adolescents (and parents) to test the ability of the MMIs to inform potential users.
* To evaluate the MMIs in a series of trials embedded within host trials in the UK, testing their effect on recruitment and retention rates, and decision making, by comparing the effect of providing standard written participant information with provision of the MMIs either in addition to the standard written participant information or the provision of the MMIs alone.

**Design overview**

The study is divided into two phases: Phase one (development) and Phase two (evaluation). The study design is shown in Figure 3. The development phase (Phase one) involves qualitative methods followed by user testing, aiming to produce two MMIs (refer to Figure 4 for development stages of the MMIs), with generic elements relevant to any trial involving children and adolescents and a template for the addition of specific content for individual host healthcare trials. In the evaluation phase (Phase two), the two MMIs will be tested in a series of embedded trials hosted within healthcare trials (refer to Figure 5 for the phase two study design), following the addition of a small amount of host trial-specific content to the MMI. The MMIs will be tested for their impact on decisions about trial participation taken by children and adolescents and/or parents and behaviours (rates of recruitment to, and retention in, the host trials). The SPIRIT checklist describing the protocol is available as Additional file 1.

**Phase one: development**

***MMI development***

Two multimedia information resources (MMIs) will be developed (see Figure 4) that can be tested as an adjunct to printed written participant information sheets for potential child and adolescent trial participants, and their parents. Two MMIs will be developed, one for older children and their parents, and one for younger children and their parents. The overall goal is that young potential participants and their parents will use the MMIs to inform their decisions about entry and ongoing participation in the host trials. Both MMIs will have generic trial information (e.g. on randomisation, study withdrawal, confidentiality, altruism and personal benefit) and a section for trial-specific information (e.g. trial purpose, intervention, number of appointments and length). The MMIs are designed to be used by children, adolescents and their parents to assist them with making an informed decision about whether to participate in a trial.

The MMIs will be commissioned from a specialist commercial supplier, so that their appearance and functions are professional, sophisticated and contemporary. One of the MMIs will be intended for use by children and their parents, and the other by adolescents and their parents. Learning from a previous study looking at the development of MMIs for adults deciding whether to participate in healthcare trials will be incorporated into the design of the current MMIs [[47](#_ENREF_47), [50](#_ENREF_50)]. The distinct content and format of the two MMIs will be informed by the qualitative study. The qualitative and user testing data will also inform the topics included in each MMI, and the mixture of media (text, animation, video and infographics). We will also explore the potential for the MMIs to be interactive, for example, allowing children and adolescents to post questions to the host trial research team, and take mini-quizzes.

***Participatory design: Qualitative study to identify the information needs and preferences of potential users of MMIs***

Individual and focus group interviews will be undertaken with i) children and adolescents (aged 9-11 years, 12-14 years and 15-17 years) with long-term health conditions (see Box 1); ii) parents of children and adolescents with long-term health conditions; and iii) researchers and clinicians who have experience in working in children’s clinical trials. Sampling will be purposive and will aim to achieve variation with regard to age, gender, long-term health condition, trial experience, ethnicity, and socio-demographics of participants. We plan to interview 6-10 people from each participant group although we will increase the number as required until new data cease contributing to the analysis. For the clinician and researcher focus groups we will sample to ensure a range of roles are represented. The age split for children and adolescents is based approximately on children’s likely capacity for a role in assent/consent decisions, using an established three part categorisation [[51](#_ENREF_51)].

Participants will be recruited through a number of mechanisms, including Alder Hey Children’s Hospital, Generation R Young People Advisory Groups (groups with membership of children and adolescents who advise on the design of research that involves children and adolescents in the NHS) and three patient interest groups: PORT (Paediatric Oncology Reference Team), the Invisible Illness group and the UK Juvenile-onset Systemic Lupus Erythematosus (JSLE) Study Group).

Data will be collected during two rounds of individual and focus group interviews held approximately two-three months apart. Focus groups are preferred because they will enable discussion of ideas amongst participants, although the wishes of those who would opt for individual interviews will be accommodated. The first round will take place before the MMIs have been designed in order to inform their content, style and delivery. The second round will take place after draft MMIs have been produced in order to explore participants’ views on these and their suggestions for amendment.

Semi-structured individual and focus group interviews will be topic guided and focus on i) preferences for information about research and, ii) preferences for content, style and delivery of the MMI. Participants will be prompted to discuss items of information adapted from a study [[52](#_ENREF_52)] of adult trial participants’ information needs, and items of information identified from a study of children and adolescents’ trial experiences [[53](#_ENREF_53)]. Items will include: why the trial is being done; whether the child or adolescent has to take part or not; whether the participant will benefit personally from taking part; and who will know the child or adolescent is taking part.

Participants will also be prompted about their preferences for how the MMI looks and functions as informed by the website industry Webby Awards criteria [[54](#_ENREF_54)] including: general needs and preferences for MMI content; potential for interactivity (e.g. question posting, quizzes); and how the information should be presented (for example whether people should receive the printed information sheet before or after the MMI).

A pilot focus group will comprise younger children (6-8 years old) and involve showing them the developed MMI to explore their perspectives on whether the MMI is easy for them to use and understand the information provided.

Where possible, the two rounds of data collection will include the same participants to facilitate respondent validation of the ongoing analysis, with some replacement for the second round, when required. Each focus group will have between four and ten participants and be approximately 90 minutes in duration. Where participants prefer they will be offered an individual interview either face-to-face or via Skype.

All individual and focus group interviews will be audio-recorded and transcribed verbatim.

***Qualitative data analysis to inform the development of the MMIs***

Analysis of qualitative data will be thematic and focus on identifying what information is important for children, adolescents and their parents when deciding to participate in a trial and their thoughts on the design aspects of the MMIs. Line by line coding will be undertaken to identify key themes within each transcript. Analysis will be led by one researcher with guidance provided by a qualitative research expert (BY) with regular meetings to discuss the data interpretation. The codes will be grouped into themes and organised using NVivo version 10 software. Following the principles of participatory design, the findings on the needs and preferences of potential users will inform the development of two prototype MMIs. We will work with patient and public involvement (PPI) members, seeking their thoughts on how to apply the findings into the development and the design of the MMIs. The MMIs will be informed directly based on the data obtained in the individual and focus group interviews. Where the views of the different participant groups (children/adolescents, parents and clinicians) diverge markedly, we will focus on the needs and preferences of children and adolescents.

***User testing***

Once the two MMI prototypes have been developed, the MMIs will undergo user testing. We will adapt the method of user testing employed in the development of printed information, including Participant Information Sheets for trials [[34](#_ENREF_34)]. This involves an iterative process with changes being made to the MMI in response to the data received. We anticipate having two rounds of user testing, with changes made to the MMIs, as required, after the first round. User testing involves small participant samples to generate quantitative data, in which data patterns are interpreted to identify any problems with a piece of information that may be responsive to change. Participants will be observed using the MMIs and then participate in brief structured interviews about the MMIs. This will involve testing participants’ knowledge and understanding of the information in the MMIs and asking them to indicate where in the MMI this information is located. The generated quantitative data are indicative, not definitive, and not analysed statistically. The emphasis is on identifying aspects of the information resource that might hinder understanding.

***User testing sampling***

Participants for the user testing will be recruited via a number of primary and secondary schools in Yorkshire, United Kingdom and aim for a diverse sample of participants in terms of ethnicity, socioeconomic status and levels of academic ability and including some participants who have English as a second language. Individuals who participated in the qualitative study will not be eligible for the user testing, as user testing produces its most valid results with participants who are not already familiar with the intervention being tested [[32](#_ENREF_32)].

We will use the conventional sampling method in user testing - rounds of 20 participants [add reference - [Kushniruk AW](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kushniruk%20AW%5BAuthor%5D&cauthor=true&cauthor_uid=15016386), [Patel VL](https://www.ncbi.nlm.nih.gov/pubmed/?term=Patel%20VL%5BAuthor%5D&cauthor=true&cauthor_uid=15016386). 2004]. In the testing of the MMI intended for older children and adolescents the samples of 20 will comprise a mix of parents, children and adolescents (aiming to achieve a spread of ages across the 12-17 years range). For the less complex MMI, rounds will comprise 10 parents and 10 younger children, aiming to achieve a spread across ages 6-11 years, with parents and children using the MMI together.

For each MMI, the two rounds of user testing will use different participants, to remove any effect of prior learning. We will ensure that the samples in the two rounds have similar profiles in terms of age and gender, to better indicate problems in the MMIs requiring change.

***User testing data analysis***

The data derived from user testing interviews will be analysed quantitatively, although data are indicative (e.g. 80 per cent cannot find a particular piece of information). Each item on the questionnaire will derive the following scoring criteria: finding (found; found with difficulty, i.e. found but only after a set time, usually >3 minutes; or not found); understanding (understood; understood with difficulty, i.e. understood but only after question rewording or repetition; not understood).

**Phase two: evaluation of MMIs**

***Embedded trials of MMIs within host clinical trials - design***

The effectiveness of the two MMIs will be evaluated in a series of trials embedded within six host trials in the UK (See Figure 5 for phase 2 design) that are recruiting children and adolescents with long-term health conditions, using methods we have developed previously [[47](#_ENREF_47)]. That is, participants in each host trial will be allocated randomly to one of two or more different intervention groups. The embedded trial (aka nested trial or ‘trial within a trial’) will be run with potential participants in each host trial – these people will be allocated randomly to receive either the MMI plus the printed information, the MMI alone, or the printed information alone, to evaluate their relative effects on recruitment rates (and the secondary outcomes).

The objective is to test the effects of the MMIs on cognitions and behaviours. The primary outcome will be whether rates of recruitment to the host trials are increased. We will also test (a) whether individuals who see the MMI(s) make a more informed decision about trial participation (or not); (b) whether rates of retention in the host clinical trials are increased; and (c) whether individuals are more satisfied with the process of consent or assent.

Recruitment of host trials will occur through the NIHR Clinical Research Network (CRN), funding bodies and through Investigator networks. In previous qualitative work, we have identified that while triallists welcome the idea of embedding trials of recruitment interventions in their studies, these need to be compatible with the host trial design and not impose extra workload [[55](#_ENREF_55)]. In the embedded trials, allocation to groups will be achieved by random number generator. Particularly in trials in which we use individual randomisation to the MMIs, it will be practicably very difficult to achieve concealment of randomisation. Trials will use individual or cluster randomisation. Masking of the allocation at outcome measurement will not be possible: the patient cannot be masked to the information format s/he will receive but, as s/he will be unaware of the embedded information trial, a lack of masking will not bias his/her responses or decisions.

***Trial eligibility criteria***

Trials will be eligible for inclusion in TRECA if they are recruiting within the UK and involve testing an intervention with children and adolescents who have a long-term health condition. Within each embedded trial, participants will be children and adolescents being asked to participate in the host healthcare trial and/or their parents. This is critical, as it means that the host trial and the embedded trial have different sample sizes. For the host trial the sample comprises those children and adolescents/parents agreeing to participate; for the embedded trial of the MMIs the sample comprises those asked to participate. In some trials, the number asked to participate is a much larger, often more than double the host trial sample size.

Eligible trials should ideally have sufficient sample size to detect a difference between groups in the embedded trial; trials will be using only printed or video participant information materials as standard (i.e. not already including an MMI); and will be recruiting at least some children and adolescents who have the potential to contribute to a decision about consent or assent to participation in the trial. Trials will not be included if they are only recruiting children too young to understand an MMI (for example children aged under 5 years), or only children with intellectual impairment such that understanding or use of the MMI is not possible.

We will aim to ensure that eligible trials vary with respect to the following features: the long-term health condition (using PRISM study criteria); the age of children and adolescents being recruited into the trial; host trials unit; the type of intervention (e.g. pharmaceutical; physical therapy; psychological) and the way that the MMI will be presented to patients (for example, parent and child viewing together versus adolescent viewing separately to parent)

***Method of embedding MMI into trials***

Each of the embedded trials will use a three arm design, in which individuals will receive the standard written trial participant information sheet (PIS) alone, the standard PIS in addition to the MMI, or the MMI alone (see Figure 3). We will consider making the written PIS available via the MMI – for example, by a link within the MMI to read or print the PIS document. This would have the advantage of being more efficient, allowing people to access both the MMI and the PIS via the computer. However we will consider important practical concerns such as text readability on screens and participant preferences, and so will seek the opinions of participants in the focus groups during the development study phase. We will also measure the number of page views and the frequency which individual elements of the MMI are viewed.

Patients allocated to the control arm of the embedded trial will be given the printed PIS only (as is usual). Those allocated to one of the intervention arms will receive either the MMI alone or the printed PIS and the MMI(s). We will not determine the order in which participants access the PIS and MMI (for those participants who receive both) and will leave this for the host trial to determine, to suit the practical demands of patient recruitment. However we will ask the host trial to record the order in which participants are given and access the PIS/MMI, and report this observation in the report of each embedded trial. The MMIs will be presented in the clinic on a computer or dedicated tablet computer. Participants will also be able to access the MMIs at home (via smartphone or a tablet or PC) via a link that is emailed to them. In some circumstances, home viewing will take place before the patient’s decision on clinical trial participation has been taken. Some patients will also want to be given access to the MMI after they have decided to take part in the host healthcare trial, just as they would if they had been given standard printed information only.

***Outcome measures***

The primary outcome will be the rates of recruitment to each host trial. We will calculate the proportion of patients who agree to participate from the total number approached, for each arm of the embedded trial. This study is investigating whether MMIs improve the quality of decision making, related to individuals being more informed about the trial. Improved decision making may have no impact on trial recruitment rates, although it is also possible that it could either increase or decrease rates as a result of individuals being more informed. It is therefore important that we also measure secondary outcomes of retention in the trials, and quality of decision-making. We will measure retention by obtaining data on the number and timing of drop outs from each host trial. The quality of decision-making by potential host trial participants will be measured through the completion by children, adolescents and parents (as relevant) of a decisional scale, adapted from one used within the REFORM trial [56] and drawing conceptually on the SURE [[5](#_ENREF_56" \o "Parayre, 2013 #118)7] and DelibeRATE scales [[5](#_ENREF_57" \o "Gillies, 2014 #120)8, [5](#_ENREF_58" \o "Sivell, 2012 #242)9]. We will report study results in line with published guidelines [60].

***Sampling considerations***

The projected effect of the MMI interventions will vary in size according to the setting of the host trial, the background recruitment rate, and the intervention being tested in the host trial. This makes it difficult to establish a sample size calculation for each of the six embedded trials. The effectiveness of the MMIs is being assessed against three outcome measures: host trial recruitment rate; quality of decision making on participation (or not); host trial retention rate. Results from each embedded trial will be combined in a prospective meta-analysis for decision scores and recruitment rate data from all six host trials participating in the TRECA project.

**Patient and public involvement**

The Investigators and research team have a strong commitment to public and patient involvement (PPI) in the TRECA Study. TRECA has a Patient and Parent Advisory Group which will play a key role in reviewing, and providing input into documentation used in the various stages of the study, including topic guides and prototype MMIs. The Patient and Parent Advisory Group will also participate in the piloting of user testing questionnaires to ensure that the question wording and length are appropriate. Two members of the Patient and Parent Advisory Group are also members of the TRECA Study Advisory Group and one or two PPI members will be involved in co-facilitation of the second set of focus groups.

**Discussion**

Whilst trials have been undertaken for many decades in medicine, limited data is available about the decision-making processes for trial participants, and which information is important for them when considering whether to participate [[2](#_ENREF_2), [21](#_ENREF_21), [52](#_ENREF_52)]. Studies that have examined the information needed for potential participants to make such decisions often do not include the level of detail that participants wanted to receive [[52](#_ENREF_52)]. The numbers of studies looking at this issue in relation to children, adolescents and their parents, is limited [[19](#_ENREF_19), [20](#_ENREF_20), [22](#_ENREF_22), [53](#_ENREF_53)].

The TRECA study will identify the information that children and adolescents consider to be most important when deciding whether or not to participate in clinical trials. Informed by the principles of participatory design, we will produce MMIs which aim to meet children, adolescents and their parents’ needs and preferences for information content and presentation. In particular, this should lead to improved patient information resources which offer relevant information in a way that is accessible to all potential participants, whilst also increasing their understanding of clinical trials in general. Ultimately, it is anticipated that improving participant information resources will increase participation in clinical trials. Specifically, this study will lead to the development of two MMIs which are suitable for children and adolescents who are invited to future clinical trials. The findings may also be of use to researchers in different settings, such as education or mental health, in order to better inform and recruit participants to studies. It may also identify principles that are transferable to other medical settings where providing accessible information is crucial, for example regarding patient decisions about hospital procedures or treatment options.

Results from the TRECA study will be published in peer-reviewed journals and disseminated widely through conferences and events. Where possible we will also use social media to publicise the findings. In particular we will aim to engage with health charities, self-help groups and lobbyists, with a view to informing children and adolescents with a variety of long-term health conditions who may be involved in research.

**Trial status**

Phase one of the study has commenced. Recruitment for phase two has not yet commenced.

**List of abbreviations**

CRN: Clinical Research Network; MMI: multimedia information; NHS: National Health Service; NIHR: National Institute for Health Research; PIS: Participant Information Sheet; PPI: patient and public involvement; TRECA: TRials Engagement in Children and Adolescents.

**Declarations**

**Ethics approval and consent to participate**

Approval was received on 13 April 2016 from The Yorkshire and The Humber-Sheffield Research Ethics Committee (project ID 16/YH/0158) and the UK Health Research Authority for phase 1 (IRAS ID: 195396). Substantial ethics amendment will be sought during 2017 to conduct each of the six recruited trials. Written informed consent will be obtained by the researchers from all participants in the study. For children and adolescents who are approached to participate in the study, consent will be sought from their parents or legally authorised representative (LAR).

**Consent for publication**

Not applicable

**Availability of data and material**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The authors wish to acknowledge the National Institute of Health Research (NIHR) Health Services and Delivery Research funding for the TRECA study (NIHR HS&DR Project: 14/21/21). The NIHR did not have a role in the design of the study or the writing of this manuscript. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Authors' contributions**

JM-K drafted the manuscript. PK led the development of the study design with specific input from PBower, JG and BY. RS, PBaines, IW, CS, CG, JP and SH all contributed to the development and revision of the manuscript. All authors read and approved the manuscript.

**Acknowledgements**

The authors wish to acknowledge Jo Rick, Adwoa Hughes Morley and Nicola Small who provided advice based on their experiences with the MRC START study. We thank the TRECA study Patient and Parent Advisory Group for their contributions to the study.

**References**

1. Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrom M, Johansen M, Taskila TK, Sullivan FM, Wilson S, Jackson C, et al:Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open 2013; 3.

2. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R:Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999; 52**:**1143-1156.

3. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C:What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006; 7**:**9.

4. Bower P, Wilson S, Mathers N:Short report: how often do UK primary care trials face recruitment delays? Fam Pract 2007; 24**:**601-603.

5. Martin-Kerry JM, Lamont TJ, Keightley A, Calache H, Martin R, Floate R, Princi K, de Silva AM:Practical considerations for conducting dental clinical trials in primary care. Br Dent J 2015; 218**:**629-634.

6. Haidich AB, Ioannidis JP:Patterns of patient enrollment in randomized controlled trials. J Clin Epidemiol 2001; 54**:**877-883.

7. Modi N, Clark H, Wolfe I, Costello A, Budge H, Goodier R, Hyde MJ, Lumsden D, Prayle A, Roland D:A healthy nation: strengthening child health research in the UK. Lancet 2013; 381**:**73-87.

8. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C:Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy 1999; 4**:**112-121.

9. Joseph PD, Craig JC, Caldwell PH:Clinical trials in children. Br J Clin Pharmacol 2013; 79**:**357-369.

10. Chappuy H, Doz F, Blanche S, Gentet JC, Treluyer JM:Children's views on their involvement in clinical research. Pediatr Blood Cancer 2008; 50**:**1043-1046.

11. Rocchi F, Tomasi P:The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res 2011; 64**:**169-175.

12. Klassen TP, Hartling L, Craig JC, Offringa M:Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med 2008; 5**:**e172.

13. Cohen E, Goldman RD, Ragone A, Uleryk E, Atenafu EG, Siddiqui U, Mahmoud N, Parkin PC:Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985-2005. Arch Pediatr Adolesc Med 2010; 164**:**283-288.

14. Caldwell PH, Butow PN, Craig JC:Pediatricians' attitudes toward randomized controlled trials involving children. J Pediatr 2002; 141**:**798-803.

15. Menzies J, Duncan H, Morrs K, Marriott J: Recruitment to pharmacokinetic research in children: what are the strategies that improve recruitment and the barriers that impede it? A systematic review of the literature. In *Br J Clin Pharmacol*. Wiley-Blackwell 2012

16. Kaguelidou F, Amiel P, Blachier A, Iliescu C, Roze JC, Tsimaratos M, Brandt C, Kassai-Koupai B, Jacqz-Aigrain E, Gaultier C, Alberti C:Recruitment in pediatric clinical research was influenced by study characteristics and pediatricians' perceptions: a multicenter survey. J Clin Epidemiol 2013; 66**:**1151-1157.

17. Woolfall K, Shilling V, Hickey H, Smyth RL, Sowden E, Williamson PR, Young B:Parents' agendas in paediatric clinical trial recruitment are different from researchers' and often remain unvoiced: a qualitative study. PLoS ONE 2013; 8**:**e67352.

18. Hoberman A, Shaikh N, Bhatnagar S, Haralam MA, Kearney DH, Colborn DK, Kienholz ML, Wang L, Bunker CH, Keren R, et al:Factors that influence parental decisions to participate in clinical research: consenters vs nonconsenters. JAMA Pediatr 2013; 167**:**561-566.

19. Varma S, Jenkins T, Wendler D:How do children and parents make decisions about pediatric clinical research? J Pediatr Hematol Oncol 2008; 30**:**823-828.

20. Fisher HR, McKevitt C, Boaz A:Why do parents enroll their children in research: a narrative synthesis. J Med Ethics 2011; 37**:**544-551.

21. Behrendt C, Golz T, Roesler C, Bertz H, Wunsch A:What do our patients understand about their trial participation? Assessing patients' understanding of their informed consent consultation about randomised clinical trials. J Med Ethics 2011; 37**:**74-80.

22. Caldwell PH, Dans L, de Vries MC, Newman Ba Hons J, Sammons H, Spriggs MBM, Tambe P, Van't Hoff W, Woolfall K, Young B, Offringa M:Standard 1: consent and recruitment. Pediatrics 2012; 129 Suppl 3**:**S118-123.

23. Tarnowski KJ, Allen DM, Mayhall C, Kelly PA:Readability of pediatric biomedical research informed consent forms. Pediatrics 1990; 85**:**58-62.

24. Ogloff JR, Otto RK:Are research participants truly informed? Readability of informed consent forms used in research. Ethics Behav 1991; 1**:**239-252.

25. Eder ML, Yamokoski AD, Wittmann PW, Kodish ED:Improving informed consent: suggestions from parents of children with leukemia. Pediatrics 2007; 119**:**e849-859.

26. Masty J, Fisher C:A Goodness-of-Fit Approach to Informed Consent for Pediatric Intervention Research. Ethics & Behavior 2008; 18**:**139-160.

27. Stead M, Eadie D, Gordon D, Angus K:"Hello, hello--it's English I speak!": a qualitative exploration of patients' understanding of the science of clinical trials. J Med Ethics 2005; 31**:**664-669.

28. Tait AR, Voepel-Lewis T, Levine R:Using digital multimedia to improve parents' and children's understanding of clinical trials. Arch Dis Child 2015; 100**:**589-593.

29. Shilling V, Williamson PR, Hickey H, Sowden E, Beresford MW, Smyth RL, Young B:Communication about children's clinical trials as observed and experienced: qualitative study of parents and practitioners. PLoS ONE 2011; 6**:**e21604.

30. Tait AR, Voepel-Lewis T:Digital multimedia: a new approach for informed consent? JAMA 2015; 313**:**463-464.

31. Armstrong N, Dixon-Woods M, Thomas A, Rusk G, Tarrant C:Do informed consent documents for cancer trials do what they should? A study of manifest and latent functions. Sociol Health Illn 2012; 34**:**1230-1245.

32. Knapp P, Raynor D, Silcock J, Parkinson B:Performance-based readability testing of participant information for a Phase 3 IVF trial. Trials 2009; 10**:**79.

33. Knapp P, Raynor DK, Silcock J, Parkinson B:Performance-based readability testing of participant materials for a phase I trial: TGN1412. J Med Ethics 2009; 35**:**573-578.

34. Knapp P, Raynor DK, Silcock J, Parkinson B:Can user testing of a clinical trial patient information sheet make it fit-for-purpose?--a randomized controlled trial. BMC Med 2011; 9**:**89.

35. Hutchison C, Cowan C, McMahon T, Paul J:A randomised controlled study of an audiovisual patient information intervention on informed consent and recruitment to cancer clinical trials. Br J Cancer 2007; 97**:**705-711.

36. Shneerson C, Windle R, Cox K:Innovating information-delivery for potential clinical trials participants. What do patients want from multi-media resources? Patient Educ Couns 2013; 90**:**111-117.

37. Höffler TN, Leutner D:Instructional animation versus static pictures: A meta-analysis. Learning and Instruction 2007; 17**:**722-738.

38. Savage I, Goodyer L:Providing information on metered dose inhaler technique: is multimedia as effective as print? Fam Pract 2003; 20**:**552-557.

39. Hopper KD, Zajdel M, Hulse SF, Yoanidis NR, TenHave TR, Labuski MR, Houts PS, Brensinger CM, Hartman DS:Interactive method of informing patients of the risks of intravenous contrast media. Radiology 1994; 192**:**67-71.

40. Krishna S, Francisco BD, Balas EA, Konig P, Graff GR, Madsen RW:Internet-enabled interactive multimedia asthma education program: a randomized trial. Pediatrics 2003; 111**:**503-510.

41. Wilson EA, Makoul G, Bojarski EA, Bailey SC, Waite KR, Rapp DN, Baker DW, Wolf MS:Comparative analysis of print and multimedia health materials: a review of the literature. Patient Educ Couns 2012; 89**:**7-14.

42. Schenker Y, Fernandez A, Sudore R, Schillinger D:Interventions to improve patient comprehension in informed consent for medical and surgical procedures: a systematic review. Med Decis Making 2011; 31**:**151-173.

43. Kinnersley P, Phillips K, Savage K, Kelly MJ, Farrell E, Morgan B, Whistance R, Lewis V, Mann MK, Stephens BL, et al:Interventions to promote informed consent for patients undergoing surgical and other invasive healthcare procedures. Cochrane Database Syst Rev 2013; 7**:**Cd009445.

44. Nishimura A, Carey J, Erwin PJ, Tilburt JC, Murad MH, McCormick JB:Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials. BMC Med Ethics 2013; 14**:**28.

45. Friedlander JA, Loeben GS, Finnegan PK, Puma AE, Zhang X, de Zoeten EF, Piccoli DA, Mamula P:A novel method to enhance informed consent: a prospective and randomised trial of form-based versus electronic assisted informed consent in paediatric endoscopy. J Med Ethics 2011; 37**:**194-200.

46. Bower P, Collier D, Eldridge S, Graffy J, Kennedy A, Knapp P, Hughes-Morley A, Rick J, Salisbury C, Small N:A multimedia intervention to enhance recruitment to clinical trials in primary care and community settings: process of development and evaluation. Trials 2013; 14**:**P90.

47. Rick J, Graffy J, Knapp P, Small N, Collier DJ, Eldridge S, Kennedy A, Salisbury C, Treweek S, Torgerson D, et al:Systematic techniques for assisting recruitment to trials (START): study protocol for embedded, randomized controlled trials. Trials 2014; 15**:**407.

48. Blake K, Holbrook JT, Antal H, Shade D, Bunnell HT, McCahan SM, Wise RA, Pennington C, Garfinkel P, Wysocki T:Use of mobile devices and the internet for multimedia informed consent delivery and data entry in a pediatric asthma trial: Study design and rationale. Contemp Clin Trials 2015; 42**:**105-118.

49. Department of Health: Children and Young People’s Health Outcomes Forum: Report of Long-term Conditions, Disability and Palliative Care Subgroup. London; 2012.

50. Bower P, Brueton V, Gamble C, Treweek S, Smith CT, Young B, Williamson P:Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials 2014; 15**:**399.

51. Nuffield Council on Bioethics: Children and clinical research: ethical issues. London; 2015.

52. Kirkby HM, Calvert M, Draper H, Keeley T, Wilson S:What potential research participants want to know about research: a systematic review. BMJ open 2012; 2**:**e000509.

53. Luchtenberg M, Maeckelberghe E, Locock L, Powell L, Verhagen AA:Young People's Experiences of Participation in Clinical Trials: Reasons for Taking Part. Am J Bioeth 2015; 15**:**3-13.

54. Awards TW:Webby Awards Judging Criteria. 2015.

55. Graffy J, Bower P, Ward E, Wallace P, Delaney B, Kinmonth AL, Collier D, Miller J:Trials within trials? Researcher, funder and ethical perspectives on the practicality and acceptability of nesting trials of recruitment methods in existing primary care trials. BMC Med Res Methodol 2010; 10**:**38.

56. Parayre AF, Labrecque M, Rousseau M, Turcotte S, Légaré F:Validation of SURE, a four-item clinical checklist for detecting decisional conflict in patients. Med Decis Making 2013**:**0272989X13491463.

57. Knapp P, Graffy J, Bower P, Rick J, Fairhurst C, Rogers S, Torgerson D, Cockayne C. Preliminary analysis of a new measure of quality of patient decision making about research participation. Presented at the 4th International Clinical Trials Methodology Conference, Liverpool, UK, May 2017.

58. Gillies K, Elwyn G, Cook J:Making a decision about trial participation: the feasibility of measuring deliberation during the informed consent process for clinical trials. Trials 2014; 15**:**1-12.

59. Sivell S, Edwards A, Manstead AS, Reed MW, Caldon L, Collins K, Clements A, Elwyn G:Increasing readiness to decide and strengthening behavioral intentions: Evaluating the impact of a web-based patient decision aid for breast cancer treatment options (BresDex: www. bresdex. com). Patient Educ Couns 2012; 88**:**209-217.

60. Madurasinghe VW:Guidelines for reporting embedded recruitment trials. Trials 2016; 17**:**27.

**Figure 1:** Possible pathway of effectiveness of multimedia information resources (MMIs)

Legend: MMI: multimedia information resource

**Figure 2:** Long-term health conditions

**Figure 3:** TRECA study design

Legend: MMI: multimedia information resource

**Figure 4:** Development of the multimedia information resources (MMIs)

Legend: MMI: multimedia information resource

**Figure 5:** Phase two study design

Legend: MMI: multimedia information resource; CRN: Clinical Research Network

**Additional files**

Additional file 1: Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) 2013 checklist. (DOC 123 kb)